Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KARD

Kardigan Inc

20.11

Aug 04 • 10:47 AM ET +0.14 (0.71%)

Healthcare Biotechnology USA Small NASD

Held by: VTI VXF GSC VTWO TMED VTWG GDOC VTWV VTHR

Scroll to Statements

Index	-
Market Cap	1.87B
Enterprise Value	2.20B
Income	-
Sales	-
Book/sh	-3.37
Cash/sh	3.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	210
IPO	Jun 18, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.42
Current Ratio	9.42
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.68
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	- -

Insider Own	33.15%
Insider Trans	22.29%
Inst Own	31.11%
Inst Trans	103.38%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.35%
SMA50	-10.01%
SMA200	-10.01%
Trades

Shs Outstand	89.34M
Shs Float	62.23M
Short Float	2.68%
Short Ratio	2.77
Short Interest	1.67M
52W High	27.00 -25.51%
52W Low	16.25 23.77%
Volatility	6.58% 8.31%
ATR (14)	1.89
RSI (14)	43.27
Beta	-
Rel Volume	0.10
Avg Volume	602.10K
Volume	14,687

Perf Week	-4.18%
Perf Month	-15.42%
Perf Quarter	-
Perf Half Y	-
Perf YTD	23.77%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	43.50
Prev Close	19.97
Price	20.11
Change	0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Initiated	TD Cowen	Buy	$46
Jul-13-26	Initiated	Leerink Partners	Outperform	$37
Jul-13-26	Initiated	JP Morgan	Overweight	$51
Jul-13-26	Initiated	Jefferies	Buy	$40

Jun-22-26 05:03PM	Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
Jun-18-26 02:03PM	Kardigan shares soar after Nasdaq debut (Investing.com)

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its "Cardiac Intelligence" platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

MBAMr. Tassos Anastasios E. Gianakakos M.Sc.

Ph.D.Dr. Jay Edelberg M.D.

Chief Financial OfficerMs. Brianne Puglisi

Co-founder & Scientific AdvisorDr. Bob McDowell Ph.D.

Co-FounderDr. Leslie A. Leinwand Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRTG GPE, LLC	10% Owner	Jun 22 '26	Buy	16.00	3,125,000	50,000,000	14,866,868	Jun 24 09:26 PM
BERNS PAUL L	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:20 PM
ARCH Venture Partners XIII, LL	Director	Jun 22 '26	Buy	16.00	1,250,000	20,000,000	15,042,035	Jun 24 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KARD

Kardigan Inc

Upgrade your Finviz experience